China Innovative Drug Stocks Slip; Nearshore Protein Falls Over 10%

A single-name drop of this size in a sector already sliding suggests company-specific pressure rather than a broad repricing, but the item gives no catalyst, so the driver stays unidentified. The breadth of decliners across several innovative drug names points to sentiment spilling beyond Nearshore Protein itself. The open question is whether the weakness is idiosyncratic or the start of a wider de-rating in the group, which would matter for the sector's ability to attract fresh capital.